-
Lonza chooses Synpromics’ novel inducible promoter platform to manufacture biopharmaceuticals
Edinburgh, UK, 16th May 2019 / Sciad Newswire / Synpromics Ltd, the leader in gene control, and Lonza Pharma & Biotech announce a partnership for the commercialisation of a number of inducible promoters to improve the manufacturing of biopharmaceuticals. The commercial agreement with Lonza follows the award of an Innovate UK grant to Synpromics announced on 23 April 2018. Lonza and…
-
Atelerix Raises Follow-on Funding Round of £700,000
Cell encapsulation for transport of cells and tissues at room temperature Cambridge, UK and Newcastle, UK, 9th May 2019 / Sciad Newswire / Atelerix, creator of an innovative cell encapsulation technology, today announces it has closed a second round of funding of £700,000 to accelerate development of its cell transport products to market. Atelerix’s products are used for the…
-
Watson-Marlow Fluid Technology Group announces strong growth driven by success across key markets
Sales results drive increased profits Photo supplied courtesy of the National Institute for Bioprocessing Research and Training (NIBRT), showing their world class facility in Dublin Falmouth, UK, 9th May 2019 / Sciad Newswire / In the recently published 2018 annual report, Watson-Marlow Fluid Technology Group (WMFTG), a Spirax-Sarco Engineering Company, reported excellent sales of over £265 million, driven by the continued growth of key…
-
Watson-Marlow Fluid Technology Group expands BioPure gasket range
New materials provide comprehensive options for all biopharmaceutical production processes offering confidence in fluid path validation Falmouth, UK, 2nd May 2019 / Sciad Newswire / Watson-Marlow Fluid Technology Group (WMFTG) announces the launch of the expanded BioPure gasket range, using new materials to cover a wider range of applications to meet the high level of demand for consistent…
-
Solentim and SAL Scientific announce partnership for novel growth supplements in cell line development
Bournemouth, UK, and Fordingbridge, UK, 25th April 2019 / Sciad Newswire / Solentim, the global leader in cell line development (CLD) imaging instrumentation, and SAL Scientific, a leading provider of growth enhancing animal-free cell culture reagents, are pleased to announce a new strategic partnership. The collaboration will further optimise CLD workflow by supplying novel supplements which substantially improve…
-
UK biotech booms 65% since 2016 as sector attracts record investment
The UK biotech industry is booming, with the number of research and development (R&D) companies increasing by 65% in just over three years, according to a new report by investment manager Downing LLP. The sector is attracting record levels of funding despite Brexit uncertainties, with annual investment reaching £2.2 billion in 2018, up 85% from…
-
Valitacell and Solentim secure €3.5m funding to optimise the development of new biologics and cell therapies
A consortium, consisting of Valitacell, Solentim and Microcoat, has been awarded €2.5million under the highly competitive H2020 Fast Track to Innovation (FTI) initiative, and a further €1million from other sources Bournemouth, UK and Dublin, Ireland, 27th March 2019 / Sciad Newswire / Solentim and Valitacell announce a total of €3.5m funding to produce an integrated platform to deposit, culture,…
-
Life Science Integrates launches new Bio Integrates to address the biggest challenges impacting the pharma and biotech sector
London, UK, 21st March 2019 / Sciad Newswire / Inspired by the success of Pharma Integrates, Life Science Integrates has introduced the new Bio Integrates conference, to be held at the Grange Tower Bridge Hotel, London, on the 22ndMay 2019. This one-day gathering of start-ups, SMEs and emerging companies will provide a platform to discuss the major challenges impacting the pharma and…
-
N-SIDE launches new innovative software for end-to-end clinical supply chain optimization
Unique management tool for minimizing costs, drug waste and risk Belgium, 12th March 2019 / Sciad Newswire / N-SIDE, a global software consulting company specializing in advanced analytics technologies, today announces the launch of the N-SIDE Suite for Clinical Trials. The new product is the only one on the market that optimizes the entire clinical trial supply chain…
-
Procarta announces €1.5 million investment for new class of antibiotics to combat antimicrobial resistance
Stevenage, UK, 5th March 2019 / Sciad Newswire / Procarta Biosystems, a privately held UK-based biotech company, today announced €1.5m of new funding from the Novo Holdings REPAIR Impact Fund to support development of novel therapies to combat antimicrobial resistance (AMR). The new funding will be used to develop a pipeline of an entirely new class of antibiotic…